A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults (Scientific reports, 2024)

(untitled) - Iwata, S; Pollard, AJ; Tada, Y; Omoto, S; Shibata, RY; Igarashi, K; Hasegawa, T; Ariyasu, M; Sonoyama, T